Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel
NASDAQ:FEMY

Femasys 5/8/2025 Earnings Report

Femasys logo
$0.36 +0.01 (+1.74%)
Closing price 04:00 PM Eastern
Extended Trading
$0.36 +0.00 (+0.61%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Femasys EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.17
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Femasys Revenue Results

Actual Revenue
$0.34 million
Expected Revenue
$1.14 million
Beat/Miss
Missed by -$801.00 thousand
YoY Revenue Growth
N/A

Femasys Announcement Details

Quarter
Date
5/8/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Femasys Earnings Headlines

Femasys updates corporate presentation on women’s health portfolio
May 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/femasys-updates-corporate-presentation-on-womens-health-portfolio?utm_source=marketbeat.com&utm_medium=referral
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
May 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/13/3294028/0/en/femasys-expands-fertility-care-portfolio-in-europe-with-ce-mark-approval-for-femhsg-catheter.html
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, Amazon, Snap, and Block have done the same. Most assume this is about AI - but investor Porter Stansberry says the real driver runs far deeper. Goldman Sachs estimates 12,400 Americans are being financially harmed every day by this shift, while others grow wealthier. Stansberry - who predicted the internet economy's rise and recommended Amazon, Qualcomm, and Texas Instruments before they were household names - is now releasing a new investigation he calls The Final Displacement.tc pixel
May 18 at 1:00 AM  |  Porter & Company (Ad)
Femasys Inc.: Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
May 9, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68446325-femasys-inc-femasys-announces-financial-results-for-quarter-ended-march-31-2026-and-provides-corporate-update-399.htm
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
May 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/08/3291326/0/en/femasys-announces-financial-results-for-quarter-ended-march-31-2026-and-provides-corporate-update.html
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
May 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287801/0/en/femasys-enables-ob-gyns-to-deliver-first-line-fertility-treatment-with-initial-commercial-use-of-femaseed-complete.html
See More Femasys Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email.

About Femasys

Femasys (NASDAQ:FEMY) International, Inc. is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography. This system is intended to facilitate earlier and more accurate diagnosis of intrauterine abnormalities such as polyps, fibroids and adhesions. Femasys is also developing a pipeline of complementary devices aimed at expanding its portfolio of interventional gynecological tools.

Femasys is listed on the Nasdaq under the ticker symbol FEMY and is incorporated in Delaware with principal executive offices in Beijing, China. The company’s leadership team includes medical device veterans with deep experience in product development, regulatory affairs and commercial strategy. Femasys continues to pursue regulatory clearances in key markets, including CE marking in Europe, while exploring opportunities to introduce its technologies across Asia, North America and other regions.

View Femasys Profile
Earnings Tools